Bovine Lactoferrin Market Size

Bovine Lactoferrin Marketsize was valued at USD 500.85 Million in 2023 and is expected to reach USD 2014.4 Million by the end of 2036, registering around 11.3% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of bovine lactoferrin is assessed at USD 551.79 Million. The growth of the market can be attributed to the worldwide proliferation of awareness regarding health, and diet among people. Furthermore, as an iron-binding protein, lactoferrin aids in treating diarrhea, hepatitis C, and intestinal ulcers. It is an ingredient that serves as an antioxidant against the wide variety of bacterial and viral infections, which have been increasing over time. Such a factor gives a notable hike to the increasing demand for bovine lactoferrin. According to the Centers for Disease Control and Prevention, in 2021, 1,899 (0.2%) of 1,081,671 samples tested positive for influenza viruses (713 (7.5%) for influenza A and 1,186 (7.5%) for influenza B) in the United States. Over the same period, 61.4% of influenza-positive samples were influenza A, while 38.6% were of influenza B. Thus, the rising prevalence of various virus spreads is estimated to fuel the global bovine lactoferrin market throughout the forecast period.

In addition to these, factors that are believed to fuel the market growth of bovine lactoferrin include the worldwide rise in the demand for convenient feeding, which has pushed the demand for nutrient-rich supplements and milk as infant food among working mothers across the globe. Additionally, the rising use of lactoferrin to treat the low ratio of iron in pregnant women is another significant factor that is boosting market growth. Furthermore, bovine lactoferrin consists of outstanding anti-inflammatory, antiviral, anti-parasitic, anti-bacterial, and anti-allergic properties, which make it a preferred substance to be used in the pharmaceutical sector, personal care, and hygiene products. For instance, it was observed in a clinical study that the ability of lactoferrin to mitigate adversely charged microbial molecules, such as LPS, makes an important contribution to its anti-inflammatory properties during bacterial infection. Therefore, it blocks the interaction of the LPS-binding protein with the endotoxin and blocks the adhesion of LPS with the membrane protein CD14, which in turn prevents the activation of monocytes and macrophages.